Yutrepia (inhaled treprostinil), an inhaled dry powder formulation of treprostinil for pulmonary arterial hypertension (PAH) and pulmonary hypertension (PH) associated with interstitial lung disease (PH-ILD), has been prescribed to more than 900 people with PAH and PH-ILD since its approval in the U.S. in May, according to its developer Liquidia. Overall, more than 550 patients […] The post Yutrepia beefs up exercise capacity in adults with PH-ILD in trial appeared first on Pulmonary Hypert...
